CD33 and cancer: For CD33 is overexpressed in MDSCs of cancer patients, combination therapy with gemtuzumab ozogamicin, a CD33 antibody conjugated with a cytotoxic drug from the class of calicheamicins, increased the antitumor activity of CAR T cells by depleting MDSCs [205].